5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Macrophages serve as viral reservoirs due to their resistance to apoptosis and HIV-cytopathic effects. We have previously shown that inhibitor of apoptosis proteins (IAPs) confer resistance to HIV-Vpr-induced apoptosis in normal macrophages. Herein, we show that second mitochondrial activator of caspases (SMAC) mimetics (SM) induce apoptosis of monocyte-derived macrophages (MDMs) infected in vitro with a R5-tropic laboratory strain expressing heat stable antigen, chronically infected U1 cells, and ex-vivo derived MDMs from HIV-infected individuals. To understand the mechanism governing SM-induced cell death, we show that SM-induced cell death of primary HIV-infected macrophages was independent of the acquisition of M1 phenotype following HIV infection of macrophages. Instead, SM-induced cell death was found to be mediated by IAPs as downregulation of IAPs by siRNAs induced cell death of HIV-infected macrophages. Moreover, HIV infection caused receptor interacting protein kinase-1 (RIPK1) degradation which in concert with IAP1/2 downregulation following SM treatment may result in apoptosis of macrophages. Altogether, our results show that SM selectively induce apoptosis in primary human macrophages infected in vitro with HIV possibly through RIPK1. Moreover, modulation of the IAP pathways may be a potential strategy for selective killing of HIV-infected macrophages in vivo.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.

          Inhibitor of apoptosis (IAP) proteins are antiapoptotic regulators that block cell death in response to diverse stimuli. They are expressed at elevated levels in human malignancies and are attractive targets for the development of novel cancer therapeutics. Herein, we demonstrate that small-molecule IAP antagonists bind to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs. The IAP antagonists also induce cell death that is dependent on TNF signaling and de novo protein biosynthesis. Additionally, the c-IAP proteins were found to function as regulators of NF-kappaB signaling. Through their ubiquitin E3 ligase activities c-IAP1 and c-IAP2 promote proteasomal degradation of NIK, the central ser/thr kinase in the noncanonical NF-kappaB pathway.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

            XIAP prevents apoptosis by binding to and inhibiting caspases, and this inhibition can be relieved by IAP antagonists, such as Smac/DIABLO. IAP antagonist compounds (IACs) have therefore been designed to inhibit XIAP to kill tumor cells. Because XIAP inhibits postmitochondrial caspases, caspase 8 inhibitors should not block killing by IACs. Instead, we show that apoptosis caused by an IAC is blocked by the caspase 8 inhibitor crmA and that IAP antagonists activate NF-kappaB signaling via inhibtion of cIAP1. In sensitive tumor lines, IAP antagonist induced NF-kappaB-stimulated production of TNFalpha that killed cells in an autocrine fashion. Inhibition of NF-kappaB reduced TNFalpha production, and blocking NF-kappaB activation or TNFalpha allowed tumor cells to survive IAC-induced apoptosis. Cells treated with an IAC, or those in which cIAP1 was deleted, became sensitive to apoptosis induced by exogenous TNFalpha, suggesting novel uses of these compounds in treating cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

              A small-molecule mimetic of Smac/Diablo that specifically counters the apoptosis-inhibiting activity of IAP proteins has been shown to enhance apoptosis induced by cell surface death receptors as well as chemotherapeutic drugs. Survey of a panel of 50 human non-small-cell lung cancer cell lines has revealed, surprisingly, that roughly one-quarter of these lines are sensitive to the treatment of Smac mimetic alone, suggesting that an apoptotic signal has been turned on in these cells and is held in check by IAP proteins. This signal has now been identified as the autocrine-secreted cytokine tumor necrosis factor alpha (TNFalpha). In response to autocrine TNFalpha signaling, the Smac mimetic promotes formation of a RIPK1-dependent caspase-8-activating complex, leading to apoptosis.
                Bookmark

                Author and article information

                Contributors
                ramon.edwin.caballero@gmail.com
                akumar@uottawa.ca
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                25 November 2021
                25 November 2021
                2021
                : 11
                : 22901
                Affiliations
                [1 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, , University of Ottawa, ; Ottawa, ON Canada
                [2 ]GRID grid.414148.c, ISNI 0000 0000 9402 6172, Division of Virology, , Apoptosis Research Centre, Children’s Hospital of Eastern Ontario Research Institute, ; 401 Smyth Road, Research Building 2, University of Ottawa, Ottawa, ON K1H 8L1 Canada
                [3 ]GRID grid.34428.39, ISNI 0000 0004 1936 893X, Department of Health Sciences, , Carleton University, ; Ottawa, ON Canada
                [4 ]GRID grid.412687.e, ISNI 0000 0000 9606 5108, Division of Infectious Diseases, , The Ottawa Hospital Research Institute, ; Ottawa, ON Canada
                [5 ]GRID grid.23856.3a, ISNI 0000 0004 1936 8390, Centre de recherche du CHU de Québec-Université Laval, , Université Laval, ; Québec City, QC Canada
                [6 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, Department of Pathology and Laboratory Medicine, Faculty of Medicine, , University of Ottawa, ; Ottawa, ON Canada
                Article
                2146
                10.1038/s41598-021-02146-w
                8617210
                34824340
                31d13bef-5f6a-4d49-b483-30c4dfb39840
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 15 July 2021
                : 9 November 2021
                Funding
                Funded by: Canadian Institute of Health Research
                Award ID: HOP 98830
                Award Recipient :
                Funded by: The Canadian HIV Cure Enterprise Team Grant
                Award ID: HIG-133050
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                immunology,microbiology,diseases,medical research,molecular medicine,pathogenesis
                Uncategorized
                immunology, microbiology, diseases, medical research, molecular medicine, pathogenesis

                Comments

                Comment on this article